Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

Androgen receptor (AR) and histone deacetylase 6 (HDAC6) are important targets for cancer therapy. Given that both AR antagonists and HDAC6 inhibitors modulate AR signaling, a novel AR/HDAC6 dual inhibitor is investigated for its anticancer effects in castration-resistant prostate cancer (CRPC). Zet...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Maojun, Zheng, Hao, Li, Yubin, Huang, Huichao, Min, Xiaoli, Dai, Shuyan, Zhou, Wenqiang, Chen, Zhuchu, Xu, Guangyu, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993727/
https://www.ncbi.nlm.nih.gov/pubmed/33621955
http://dx.doi.org/10.18632/aging.202554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993727/
https://www.ncbi.nlm.nih.gov/pubmed/33621955
http://dx.doi.org/10.18632/aging.202554

Ejemplares similares